Drug intelligence / Profile preview

GSK2849466

Development stage: Phase 1
Lead developer: GSK
Modality: Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

GSK2849466 is an investigational selective androgen receptor modulator (SARM) that was developed by GlaxoSmithKline (now known as GSK). The drug was designed to selectively modulate the androgen receptor, aiming to provide anabolic benefits with fewer side effects compared to traditional androgens. Its primary indications were for the treatment of cachexia and heart failure. Clinical development reached Phase I, where it was evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy male subjects using single and repeat oral dosing regimens. However, development of GSK2849466 was discontinued after completion of Phase I studies[1][2][7][9].

Other names: GSK 2849466GSK2849466GSK-2849466

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on GSK2849466.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK2849466.

Explore the full profile